We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: androgen deprivation therapy
MedXY News
EnglishTag

androgen deprivation therapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Metabolic Dysfunction Following Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer: Clinical Implications and Risks
Diabetes & Endocrinologyprostate cancermetabolic syndrome

Metabolic Dysfunction Following Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer: Clinical Implications and Risks

By MedXY|Aug 15, 2026

This study reveals a significant early onset of metabolic syndrome in men with prostate cancer treated with combined ADT and ARPI therapies, highlighting the necessity for multidisciplinary metabolic monitoring and interventions.

GnRH Agonists Linked to Accelerated Coronary Plaque Progression Compared to Antagonists in Prostate Cancer Patients
Cardiologyandrogen deprivation therapy
Cardio-Oncology

GnRH Agonists Linked to Accelerated Coronary Plaque Progression Compared to Antagonists in Prostate Cancer Patients

By MedXY|Feb 19, 2026

A randomized clinical trial demonstrates that the GnRH agonist leuprolide leads to significantly greater coronary plaque progression, specifically noncalcified plaque, compared to the antagonist relugolix in men with prostate cancer, offeri

Balancing Benefit and Harm: How Long Should Androgen Deprivation Therapy Be Given With Radiotherapy for Localized Prostate Cancer?
newsandrogen deprivation therapyprostate cancer

Balancing Benefit and Harm: How Long Should Androgen Deprivation Therapy Be Given With Radiotherapy for Localized Prostate Cancer?

By MedXY|Nov 23, 2025

An individual-patient data meta-analysis of 10,266 men shows nonlinear oncologic benefit from longer ADT with radiotherapy (diminishing beyond 9–12 months) but increasing other-cause mortality with long-term ADT; optimal duration should be

Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence
Clinical Updatesandrogen deprivation therapymetastatic hormone-sensitive prostate cancer

Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence

By MedXY|Nov 17, 2025

Comprehensive review of metformin’s role in metastatic prostate cancer with ADT highlights STAMPEDE trial’s findings: no significant overall survival benefit but metabolic side-effect mitigation. Integration of other RCTs outlin

Metformin Did Not Prevent Metabolic Syndrome During ADT but Improved Weight, Waist and HbA1c: Findings from the PRIME Phase 3 Trial
Diabetes & Endocrinologyandrogen deprivation therapymetabolic syndrome

Metformin Did Not Prevent Metabolic Syndrome During ADT but Improved Weight, Waist and HbA1c: Findings from the PRIME Phase 3 Trial

By MedXY|Nov 17, 2025

In the PRIME randomized phase 3 trial, metformin did not significantly reduce metabolic syndrome incidence in men starting androgen deprivation therapy, but produced modest, clinically relevant reductions in body weight, waist circumference

Impact of Enzalutamide on PSA Dynamics and Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Insights from the ARCHES Trial Secondary Analysis
Oncologyandrogen deprivation therapyEnzalutamide

Impact of Enzalutamide on PSA Dynamics and Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Insights from the ARCHES Trial Secondary Analysis

By MedXY|Oct 21, 2025

This secondary analysis of the ARCHES trial demonstrates that enzalutamide plus ADT improves progression-free and overall survival in mHSPC patients across PSA levels, with undetectable PSA strongly predicting favorable outcomes.

Metformin in Prostate Cancer: Revisiting Hopes and Realities After Recent Phase 3 Trials
Clinical Updatesandrogen deprivation therapyclinical trial

Metformin in Prostate Cancer: Revisiting Hopes and Realities After Recent Phase 3 Trials

By MedXY|Oct 1, 2025

Recent large RCTs show metformin does not improve survival or reduce metabolic syndrome risk in prostate cancer patients on ADT, though it modestly improves metabolic parameters.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities